Tirzepatide Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving Tirzepatide Growth

1. Market Share Gains and New Patient Starts

• Tirzepatide is rapidly capturing market share in both type 2 diabetes and obesity treatment, emerging as one of the most successful drug launches in recent years.
• A significant surge in new patient starts is fueling strong prescription growth, with high demand from both diabetes and obesity care providers.
• Eli Lilly's aggressive commercial strategy, strong physician education initiatives, and direct-to-consumer outreach are driving broad adoption across therapeutic segments.

2. Expansion Across Key Indications

• Type 2 Diabetes (Mounjaro): Approved as a once-weekly injectable GLP-1/GIP dual agonist, showing superior efficacy in HbA1c reduction and weight loss compared to existing GLP-1 therapies.
• Obesity/Weight Management (Zepbound): Recently approved for chronic weight management, with unprecedented clinical results in weight reduction driving rapid uptake.
• Cardiovascular Risk Reduction: Ongoing trials are evaluating tirzepatide's benefits in cardiovascular outcomes, a potential growth catalyst.
• Pipeline Developments: Studies in non-alcoholic steatohepatitis (NASH), obstructive sleep apnea, and heart failure with preserved ejection fraction (HFpEF) suggest significant future expansion opportunities.

3. Geographic Expansion

• Tirzepatide is rolling out globally under the brands Mounjaro (diabetes) and Zepbound (obesity), with launches in both developed and emerging markets.
• The Asia-Pacific region is expected to drive fast growth, fueled by rising obesity and diabetes prevalence, improved healthcare access, and strong demand for novel weight-loss solutions.
• Eli Lilly is significantly expanding its global manufacturing and supply capacity to address ongoing demand-supply imbalances.

4. New Indication Approvals

• FDA and EMA approvals for obesity (Zepbound) have broadened tirzepatide's treatment landscape beyond diabetes.
• Anticipated approvals in cardiovascular outcomes and obesity-related comorbidities are expected to further enhance its positioning.
• Ongoing regulatory submissions in multiple geographies will accelerate uptake and diversify revenue streams.

5. Strong Diabetes and Obesity Volume Momentum

• Tirzepatide is demonstrating robust prescription growth in both diabetes and obesity, with demand often exceeding supply.
• 2025 updates highlight sustained momentum in the obesity segment, positioning tirzepatide as a cornerstone therapy in the weight management market.
• Real-world data confirm clinical trial results, showing durable improvements in glycemic control and weight reduction across broad patient populations.

6. Competitive Differentiation and Market Trends

• Tirzepatide's dual GIP/GLP-1 mechanism delivers superior efficacy in both glucose control and weight reduction, setting a new benchmark in metabolic disease management.
• Once-weekly injection profile offers convenience and supports strong adherence compared to older antidiabetic regimens.
• Its strong efficacy in weight loss differentiates it from Ozempic and Wegovy, intensifying competition in the metabolic care market.
• Broader market trends such as the global obesity epidemic, cardiometabolic care focus, and patient preference for high-efficacy therapies strongly support tirzepatide's growth trajectory.
• Increasing reliance on Real-World Evidence (RWE) is reinforcing payer confidence, improving reimbursement, and expanding access.

Tirzepatide Recent Developments

• In September 2025, Eli Lilly and Company announced detailed results from SURPASS-PEDS, the first Phase III trial to evaluate the safety and efficacy of MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, in children and adolescents (ages 10 to less than 18) with type 2 diabetes inadequately controlled with metformin, basal insulin or both. At 30 weeks, MOUNJARO met the primary and all key secondary endpoints, achieving superior improvements in A1C and body mass index (BMI) compared to placebo. Results from the trial were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 and simultaneously published in The Lancet.
• In July 2025, Eli Lilly and Company announced topline results from SURPASS-CVOT, a first-of-its-kind head-to-head Phase III cardiovascular outcomes trial comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. MOUNJARO (tirzepatide), a GIP/GLP-1 dual receptor agonist, was compared to Trulicity (dulaglutide), a GLP-1 receptor agonist that showed a definitive cardiovascular benefit in the REWIND study. In SURPASS-CVOT, MOUNJARO achieved the primary objective by demonstrating a non-inferior rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack or stroke vs. Trulicity.

"Tirzepatide Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Tirzepatide for approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus in the 7MM. A detailed picture of Tirzepatide's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Tirzepatide for approved and potential indications. The Tirzepatide market report provides insights about Tirzepatide's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Tirzepatide performance, future market assessments inclusive of the Tirzepatide market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Tirzepatide sales forecasts, along with factors driving its market.

Tirzepatide Drug Summary

Tirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) dual receptor agonist. Tirzepatide is a single molecule that activates the body's receptors for GIP and GLP-1, which are natural incretin hormones. Both GIP and GLP-1 receptors are found in areas of the human brain important for appetite regulation. Tirzepatide decreases calorie intake, and the effects are likely mediated by affecting appetite. Tirzepatide lowers fasting and postprandial glucose, increases insulin sensitivity, decreases food intake and reduces body weight in patients with type 2 diabetes. Studies of tirzepatide in chronic kidney disease (CKD) and in morbidity/mortality in obesity (MMO) are ongoing.

Tirzepatide has been approved by the US FDA as MOUNJARO for adults with type 2 diabetes to improve glycemic control, and as ZEPBOUND for adults with obesity, or some adults who are overweight and also have at least one weight-related medical problem, to lose weight and keep it off. Additionally, ZEPBOUND is FDA-approved to treat adults with moderate-to-severe obstructive sleep apnea and obesity. Tirzepatide is also approved as MOUNJARO in some countries outside the US for adults with type 2 diabetes, obesity or those who are overweight who also have a weight-related comorbid condition. Both MOUNJARO and ZEPBOUND should be used in combination with diet and exercise. The report provides Tirzepatide's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Tirzepatide is in the Phase III stage of clinical development for the treatment of patients with Psoriatic arthritis (NCT06588296) and Type 1 diabetes mellitus (NCT06914895).

Scope of the Tirzepatide Market Report

The report provides insights into:

• A comprehensive product overview including the Tirzepatide MoA, description, dosage and administration, research and development activities in approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus.
• Elaborated details on Tirzepatide regulatory milestones and other development activities have been provided in Tirzepatide market report.
• The report also highlights Tirzepatide's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Tirzepatide market report also covers the patents information, generic entry and impact on cost cut.
• The Tirzepatide market report contains current and forecasted Tirzepatide sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Tirzepatide market report also features the SWOT analysis with analyst views for Tirzepatide in approved and potential indications.

Methodology:

The Tirzepatide market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tirzepatide Analytical Perspective by DelveInsight

• In-depth Tirzepatide Market Assessment

This Tirzepatide sales market forecast report provides a detailed market assessment of Tirzepatide for approved indications like Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Tirzepatide sales data uptil 2034.

• Tirzepatide Clinical Assessment

The Tirzepatide market report provides the clinical trials information of Tirzepatide for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Tirzepatide Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Tirzepatide Market Potential & Revenue Forecast

• Projected market size for the Tirzepatide and its key indications
• Estimated Tirzepatide sales potential (Tirzepatide peak sales forecasts)
• Tirzepatide Pricing strategies and reimbursement landscape

Tirzepatide Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Tirzepatide Market positioning compared to existing treatments
• Tirzepatide Strengths & weaknesses relative to competitors

Tirzepatide Regulatory & Commercial Milestones

• Tirzepatide Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Tirzepatide Clinical Differentiation

• Tirzepatide Efficacy & safety advantages over existing drugs
• Tirzepatide Unique selling points

Tirzepatide Market Report Highlights

• In the coming years, the Tirzepatide market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Tirzepatide companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Tirzepatide's dominance.
• Other emerging products for Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus are expected to give tough market competition to Tirzepatide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Tirzepatide in approved and potential indications.
• Analyse Tirzepatide cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Tirzepatide sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Tirzepatide in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Tirzepatide? How strong is Tirzepatide's clinical and commercial performance?
• What is Tirzepatide's clinical trial status in each individual indications such as Obesity; Sleep apnoea syndrome; Type 2 diabetes mellitus; as well as potential indications like Psoriatic arthritis and Type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Tirzepatide Manufacturers?
• What are the key designations that have been granted to Tirzepatide for approved and potential indications? How are they going to impact Tirzepatide's penetration in various geographies?
• What is the current and forecasted Tirzepatide market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Tirzepatide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Tirzepatide for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Tirzepatide? What is the duration of therapy and what are the geographical variations in cost per patient?